Treatment Considerations and Evolving Data in Advanced Melanoma After Checkpoint Inhibition

Justin Moser, MD, discusses efforts to develop a broader range of immunotherapy approaches for advanced melanoma after PD-1 inhibition.

Justin Moser, MD, discusses key considerations for second-line treatment selection for patients with melanoma who have progressed on PD-1 inhibitors.

Stergios Moschos, MD, discusses his approach to selecting from the available agents in metastatic melanoma after first-line PD-1 inhibition.

Stergios J. Moschos, MD, discusses how the use of bridging therapy can enhance the efficacy of adoptive T-cell therapies for patients with melanoma.